Welcome to Argonaut Therapeutics

Argonaut is developing novel epigenetic therapies targeting arginine methylation in cancer.

Group

Argonaut Therapeutics

Is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut Therapeutics strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.

Our mission

Argonaut Therapeutics is a precision medicine company developing transformative epigenetic therapeutics to treat cancer.

News

Argonaut Therapeutics Announces Successful Completion of Financing Round

The investment will advance Argonaut’s arginine methylation inhibitor drug candidate towards the clinic and enable…

Read More...

We are recruiting!

Investors

small logo-3
Read more
small logo-2
Read more
small logo-1
Read more